Ana Arnalich-Montiel

Prof. Dr. Ana Arnalich-Montiel

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAna Arnalich-Montiel
Ana Arnalich-Montiel
ABAlba Burgos
Alba Burgos
LPLaia Pazó-Sayós
Laia Pazó-Sayós
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
Acute ischemic stroke (AIS) is a challenging disease, which needs urgent comprehensive management. Endovascular thrombectomy (EVT), alone or combined with iv thrombolysis, is currently the most effective therapy for patients with acute ischemic stroke (AIS). However, only a limited number of patients are eligible for this time-sensitive treatment. Even though there is still significant room for improvement in the management of this group of patients, up until now there have been no alternative therapies approved for use in clinical practice. However, there is still hope, as clinical research with novel emerging therapies is now generating promising results. These drugs happen to stop or palliate some of the underlying molecular mechanisms involved in cerebral ischemia and secondary brain damage. The aim of this review is to provide a deep understanding of these mechanisms and the pathogenesis of AIS. Later, we will discuss the potential therapies that have already demonstrated, in preclinical or clinical studies, to improve the outcomes of patients with AIS.

Verified
Journal Article
Open access
PDF file
ABAlba Burgos
Alba Burgos
PRPilar Rodríguez-Rodríguez
Pilar Rodríguez-Rodríguez
AAAna Arnalich-Montiel
Ana Arnalich-Montiel
Silvia ArribasSilvia Arribas
Silvia Arribas
CFCarmen Fernández-Riveira
Carmen Fernández-Riveira
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
An aortic aneurysm (AA) is a life-threatening condition. Oxidative stress may be a common pathway linking multiple mechanisms of an AA, including vascular inflammation and metalloproteinase activity. Endovascular aneurysm repair (EVAR) is the preferred surgical approach for AA treatment. During surgery, inflammation and ischemia–reperfusion injury occur, and reactive oxygen species (ROS) play a key role in their modulation. Increased perioperative oxidative stress is associated with higher postoperative complications. The use of volatile anesthetics during surgery has been shown to reduce oxidative stress. Individual biomarkers only partially reflect the oxidative status of the patients. A global indicator of oxidative stress (OXY-SCORE) has been validated in various pathologies. This study aimed to compare the effects of the main volatile anesthetics, sevoflurane and desflurane, on oxidative status during EVAR. Eighty consecutive patients undergoing EVAR were randomized into two groups: sevoflurane and desflurane. Plasma biomarkers of oxidative damage (protein carbonylation and malondialdehyde) and antioxidant defense (total thiols, glutathione, nitrates, superoxide dismutase, and catalase activity) were measured before surgery and 24 h after EVAR. The analysis of individual biomarkers showed no significant differences between the groups. However, the OXY-SCORE was positive in the desflurane group (indicating a shift towards antioxidants) and negative in the sevoflurane group (favoring oxidants) (p < 0.044). Compared to sevoflurane, desflurane had a positive effect on oxidative stress during EVAR. The OXY-SCORE could provide a more comprehensive perspective on oxidative stress in this patient population.

Verified
Journal Article
Open access
PDF file
DMDavid Fernández Morales
David Fernández Morales
AAAna Arnalich-Montiel
Ana Arnalich-Montiel
MDMaría J. Delgado-Martos
María J. Delgado-Martos
PRPilar Rodríguez-Rodríguez
Pilar Rodríguez-Rodríguez
LPLaia Pazó-Sayós
Laia Pazó-Sayós
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
Background: Our research group has previously demonstrated the protective effect of short-term treatment with esmolol on large artery remodeling. However, whether this beneficial effect persists after treatment withdrawal remains unknown. Therefore, the aim of the present study was to investigate whether regression of thoracic aorta remodeling after a short-term esmolol treatment persists following drug withdrawal. Methods: Adult male spontaneously hypertensive rats (SHRs) received either esmolol (300 µg/kg/min) or vehicle (saline solution) by continuous infusion for 48 h. Following treatment, animals were evaluated either immediately (SHR-E 48 h group) or after withdrawal periods of 7 days (SHR-E 7 d group) or 1 month (SHR-E 1 m group). Hemodynamic parameters, thoracic aorta geometry, extracellular matrix composition (elastin and collagen), and the passive mechanical response of the arterial wall (β parameter) were assessed in all animals. Results: Forty-eight hours of esmolol treatment significantly reduced blood pressure and attenuated thoracic aortic wall thickness, external diameter, cross-sectional area, collagen content and elastic fiber density. Additionally, passive mechanical testing showed a significant reduction in the β parameter, indicating improved arterial compliance after treatment. Remarkably, these structural and mechanical benefits persisted for up to one month after withdrawal, despite the return of blood pressure to hypertensive levels. Conclusions: Protective effect of esmolol on aortic remodeling is persistent after treatment withdrawal in SHRs, perhaps independent of blood pressure.